Pooled screening with next-generation gene editing tools.

CRISPR CRISPR screen Cell engineering Gene editing Gene regulation

Journal

Current opinion in biomedical engineering
ISSN: 2468-4511
Titre abrégé: Curr Opin Biomed Eng
Pays: England
ID NLM: 101704011

Informations de publication

Date de publication:
Dec 2023
Historique:
pmc-release: 01 12 2024
medline: 15 1 2024
pubmed: 15 1 2024
entrez: 15 1 2024
Statut: ppublish

Résumé

Pooled screening creates a pool of cells with genetic variants, allowing for the simultaneous examination for changes in behavior or function. By selectively inducing mutations or perturbing expression, it enables scientists to systematically investigate the function of genes or genetic elements. Emerging gene editing tools, such as CRISPR, coupled with advances in sequencing and computational capabilities, provide growing opportunities to understand biological processes in humans, animals, and plants as well as to identify potential targets for therapeutic interventions and agricultural research. In this review, we highlight the recent advances of pooled screens using next-generation gene editing tools along with relevant challenges and describe potential future directions of this technology.

Identifiants

pubmed: 38222973
doi: 10.1016/j.cobme.2023.100479
pmc: PMC10786633
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

Declaration of interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SC is a (co)founder of EvolveImmune Tx, Cellinfinity Bio, Chen Consulting, NumericGlobal, and Chen Tech, all unrelated to this study.

Auteurs

Liqun Zhou (L)

Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
System Biology Institute, Yale University, West Haven, CT, USA.
Center for Cancer Systems Biology, Yale University, West Haven, CT, USA.
Immunobiology Program, Yale University, New Haven, CT, USA.

Luojia Yang (L)

Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
System Biology Institute, Yale University, West Haven, CT, USA.
Center for Cancer Systems Biology, Yale University, West Haven, CT, USA.
Molecular Cell Biology, Genetics, and Development Program, Yale University, New Haven, CT, USA.

Yanzhi Feng (Y)

Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
System Biology Institute, Yale University, West Haven, CT, USA.
Center for Cancer Systems Biology, Yale University, West Haven, CT, USA.
Immunobiology Program, Yale University, New Haven, CT, USA.

Sidi Chen (S)

Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
System Biology Institute, Yale University, West Haven, CT, USA.
Center for Cancer Systems Biology, Yale University, West Haven, CT, USA.
Immunobiology Program, Yale University, New Haven, CT, USA.
Molecular Cell Biology, Genetics, and Development Program, Yale University, New Haven, CT, USA.
Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
Stem Cell Center, Yale University School of Medicine, New Haven, CT, USA.
Center for Biomedical Data Science, Yale University School of Medicine, New Haven, CT, USA.

Classifications MeSH